The future of immunotherapy in advanced renal cell carcinoma: beyond PD-1/PD-L1 inhibitors

被引：0

作者：

Nuvola, Giacomo ^{[1
]}

Mollica, Veronica ^{[2
]}

Massari, Francesco ^{[2
]}

Suarez, Cristina ^{[3
]}

机构：

[1] SCIAS Hosp Barcelona, Med Oncol, Barcelona 08034, Spain

[2] Univ Bologna, IRCCS Azienda Osped, Med Oncol, I-40138 Bologna, Italy

[3] Hosp Univ Vall dHebron, Vall dHebron Inst Oncol VHIO, Med Oncol, Barcelona 08035, Spain

来源：

IMMUNOTHERAPY | 2023年 / 15卷 / 17期

关键词：

CTLA-4; ILT4; immunotherapy; kidney cancer; LAG-3; PD-1; TIGIT; OPEN-LABEL; PEMBROLIZUMAB; NIVOLUMAB; SUNITINIB; MONOTHERAPY; THERAPY; VACCINE;

D O I：

10.2217/imt-2023-0218

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页数：6

共 34 条

[1] Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial [J].

Albiges, Laurence ;

Tannir, Nizar M. ;

Burotto, Mauricio ;

McDermott, David ;

Plimack, Elizabeth R. ;

Barthelemy, Philippe ;

Porta, Camillo ;

Powles, Thomas ;

Donskov, Frede ;

George, Saby ;

Kollmannsberger, Christian K. ;

Gurney, Howard ;

Grimm, Marc-Oliver ;

Tomita, Yoshihiko ;

Castellano, Daniel ;

Rini, Brian, I ;

Choueiri, Toni K. ;

Saggi, Shruti Shally ;

McHenry, M. Brent ;

Motzer, Robert J. .

ESMO OPEN, 2020, 5 (06)

[2] Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway [J].

Boussiotis, Vassiliki A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (18) :1767-1778

[3] Microbiota: Overview and Implication in Immunotherapy-Based Cancer Treatments [J].

Brandi, Giovanni ;

Frega, Giorgio .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (11)

[4] Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study [J].

Cho, Byoung Chul ;

Abreu, Delvys Rodriguez ;

Hussein, Maen ;

Cobo, Manuel ;

Patel, Anjan J. ;

Secen, Nevena ;

Lee, Ki Hyeong ;

Massuti, Bartomeu ;

Hiret, Sandrine ;

Yang, James Chih Hsin ;

Barlesi, Fabrice ;

Lee, Dae Ho ;

Ares, Luis Paz ;

Hsieh, Robert W. ;

Patil, Namrata S. ;

Twomey, Patrick ;

Yang, Xiaoying ;

Meng, Raymond ;

Johnson, Melissa L. .

LANCET ONCOLOGY, 2022, 23 (06) :781-792

[5] Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma [J].

Choueiri, T. K. ;

Tomczak, P. ;

Park, S. H. ;

Venugopal, B. ;

Ferguson, T. ;

Chang, Y. -H. ;

Hajek, J. ;

Symeonides, S. N. ;

Lee, J. L. ;

Sarwar, N. ;

Thiery-Vuillemin, A. ;

Gross-Goupil, M. ;

Mahave, M. ;

Haas, N. B. ;

Sawrycki, P. ;

Gurney, H. ;

Chevreau, C. ;

Melichar, B. ;

Kopyltsov, E. ;

Alva, A. ;

Burke, J. M. ;

Doshi, G. ;

Topart, D. ;

Oudard, S. ;

Hammers, H. ;

Kitamura, H. ;

Bedke, J. ;

Perini, R. F. ;

Zhang, P. ;

Imai, K. ;

Willemann-Rogerio, J. ;

Quinn, D. I. ;

Powles, T. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (08) :683-694

[6] Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma [J].

Choueiri, T. K. ;

Powles, T. ;

Burotto, M. ;

Escudier, B. ;

Bourlon, M. T. ;

Zurawski, B. ;

Juarez, V. M. Oyervides ;

Hsieh, J. J. ;

Basso, U. ;

Shah, A. Y. ;

Suarez, C. ;

Hamzaj, A. ;

Goh, J. C. ;

Barrios, C. ;

Richardet, M. ;

Porta, C. ;

Kowalyszyn, R. ;

Feregrino, J. P. ;

Zolnierek, J. ;

Pook, D. ;

Kessler, E. R. ;

Tomita, Y. ;

Mizuno, R. ;

Bedke, J. ;

Zhang, J. ;

Maurer, M. A. ;

Simsek, B. ;

Ejzykowicz, F. ;

Schwab, G. M. ;

Apolo, A. B. ;

Motzer, R. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (09) :829-841

[7] The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines) [J].

De Giglio, Andrea ;

Di Federico, Alessandro ;

Nuvola, Giacomo ;

Deiana, Chiara ;

Gelsomino, Francesco .

CURRENT ONCOLOGY REPORTS, 2021, 23 (11)

[8] Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial [J].

Dizman, Nazli ;

Meza, Luis ;

Bergerot, Paulo ;

Alcantara, Marice ;

Dorff, Tanya ;

Lyou, Yung ;

Frankel, Paul ;

Cui, Yujie ;

Mira, Valerie ;

Llamas, Marian ;

Hsu, Joann ;

Zengin, Zeynep ;

Salgia, Nicholas ;

Salgia, Sabrina ;

Malhotra, Jasnoor ;

Chawla, Neal ;

Chehrazi-Raffle, Alex ;

Muddasani, Ramya ;

Gillece, John ;

Reining, Lauren ;

Trent, Jeff ;

Takahashi, Motomichi ;

Oka, Kentaro ;

Higashi, Seiya ;

Kortylewski, Marcin ;

Highlander, Sarah K. ;

Pal, Sumanta K. .

NATURE MEDICINE, 2022, 28 (04) :704-+

[9] ILT4 functions as a potential checkpoint molecule for tumor immunotherapy [J].

Gao, Aiqin ;

Sun, Yuping ;

Peng, Guangyong .

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2018, 1869 (02) :278-285

[10] Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study [J].

Hammers, Hans J. ;

Plimack, Elizabeth R. ;

Infante, Jeffrey R. ;

Rini, Brian I. ;

McDermott, David F. ;

Lewis, Lionel D. ;

Voss, Martin H. ;

Sharma, Padmanee ;

Pal, Sumanta K. ;

Razak, Albiruni R. Abdul ;

Kollmannsberger, Christian ;

Heng, Daniel Y. C. ;

Spratlin, Jennifer ;

McHenry, M. Brent ;

Amin, Asim .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (34) :3851-+

← 1 2 3 4 →